77 related articles for article (PubMed ID: 18431051)
1. Cardiac troponin T and advanced glycation end-products in hemodialysis patients.
Taki K; Tsuruta Y; Niwa T
Am J Nephrol; 2008; 28(5):701-6. PubMed ID: 18431051
[TBL] [Abstract][Full Text] [Related]
2. Olmesartan medoxomil is associated with decreased plasma AGEs, pentosidine, and N-(epsilon)-carboxymethyl-lysine levels in hemodialysis patients.
Honda H; Hosaka N; Aoshima Y; Hirai Y; Michihata T; Akizawa T
Clin Exp Hypertens; 2012; 34(1):17-23. PubMed ID: 22149003
[TBL] [Abstract][Full Text] [Related]
3. Plasma Levels of Pentosidine, Carboxymethyl-Lysine, Soluble Receptor for Advanced Glycation End Products, and Metabolic Syndrome: The Metformin Effect.
Haddad M; Knani I; Bouzidi H; Berriche O; Hammami M; Kerkeni M
Dis Markers; 2016; 2016():6248264. PubMed ID: 27829696
[TBL] [Abstract][Full Text] [Related]
4. Advanced glycation end products in children with chronic renal failure and type 1 diabetes.
Misselwitz J; Franke S; Kauf E; John U; Stein G
Pediatr Nephrol; 2002 May; 17(5):316-21. PubMed ID: 12042886
[TBL] [Abstract][Full Text] [Related]
5. Marked increases in macrophage colony-stimulating factor and interleukin-18 in maintenance hemodialysis patients: comparative study of advanced glycation end products, carboxymethyllysine and pentosidine.
Uchimura T; Motomiya Y; Okamura H; Hashiguchi T; Miura M; Uji Y; Iwamoto H; Maruyama I
Nephron; 2002 Apr; 90(4):401-7. PubMed ID: 11961398
[TBL] [Abstract][Full Text] [Related]
6. The role of advanced glycation end-products and their receptor on outcome in heart failure patients with preserved and reduced ejection fraction.
Willemsen S; Hartog JW; van Veldhuisen DJ; van der Meer P; Roze JF; Jaarsma T; Schalkwijk C; van der Horst IC; Hillege HL; Voors AA
Am Heart J; 2012 Nov; 164(5):742-749.e3. PubMed ID: 23137505
[TBL] [Abstract][Full Text] [Related]
7. Influence of hemodialysis membrane type on pentosidine plasma level, a marker of "carbonyl stress".
Jadoul M; Ueda Y; Yasuda Y; Saito A; Robert A; Ishida N; Kurokawa K; Van Ypersele De Strihou C; Miyata T
Kidney Int; 1999 Jun; 55(6):2487-92. PubMed ID: 10354298
[TBL] [Abstract][Full Text] [Related]
8. Circulating levels and dietary intake of the advanced glycation end-product marker carboxymethyl lysine in chronic kidney disease patients on conservative predialysis therapy: a pilot study.
Piroddi M; Palazzetti I; Quintaliani G; Pilolli F; Montaldi M; Valentina V; Libetta C; Galli F
J Ren Nutr; 2011 Jul; 21(4):329-39. PubMed ID: 21193322
[TBL] [Abstract][Full Text] [Related]
9. Involvement of advanced glycation end-products, pentosidine and N(epsilon)-(carboxymethyl)lysine, in doxorubicin-induced cardiomyopathy in rats.
Moriyama T; Kemi M; Okumura C; Yoshihara K; Horie T
Toxicology; 2010 Jan; 268(1-2):89-97. PubMed ID: 20004697
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
Busch M; Franke S; Wolf G; Rohde RD; Stein G;
Nephron Clin Pract; 2008; 108(4):c291-7. PubMed ID: 18434751
[TBL] [Abstract][Full Text] [Related]
11. Are advanced glycation end products cardiovascular risk factors in patients with CRF?
Stein G; Busch M; Müller A; Wendt T; Franke C; Niwa T; Franke S
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S52-6. PubMed ID: 12612953
[TBL] [Abstract][Full Text] [Related]
12. Advanced glycation end-products pentosidine and N epsilon-carboxymethyllysine are elevated in serum of patients with osteoporosis.
Hein G; Wiegand R; Lehmann G; Stein G; Franke S
Rheumatology (Oxford); 2003 Oct; 42(10):1242-6. PubMed ID: 12777635
[TBL] [Abstract][Full Text] [Related]
13. Skin-autofluorescence, a measure of tissue advanced glycation end-products (AGEs), is related to diastolic function in dialysis patients.
Hartog JW; Hummel YM; Voors AA; Schalkwijk CG; Miyata T; Huisman RM; Smit AJ; Van Veldhuisen DJ
J Card Fail; 2008 Sep; 14(7):596-602. PubMed ID: 18722326
[TBL] [Abstract][Full Text] [Related]
14. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients.
Taki K; Takayama F; Tsuruta Y; Niwa T
Kidney Int; 2006 Jul; 70(1):218-24. PubMed ID: 16723988
[TBL] [Abstract][Full Text] [Related]
15. Plasma levels of advanced glycation end products are associated with haemolysis-related organ complications in sickle cell patients.
Nur E; Brandjes DP; Schnog JJ; Otten HM; Fijnvandraat K; Schalkwijk CG; Biemond BJ;
Br J Haematol; 2010 Oct; 151(1):62-9. PubMed ID: 20678158
[TBL] [Abstract][Full Text] [Related]
16. The effect of dialysis membrane type on plasma concentrations of pentosidine, a marker of carbonyl stress, in hemodialyzed patients.
Słowik-Zyłka D; Safranow K; Dziedziejko V; Ciechanowski K; Dziewanowski K; Chlubek D
Pol Arch Med Wewn; 2009 Oct; 119(10):614-20. PubMed ID: 19847136
[TBL] [Abstract][Full Text] [Related]
17. Predictive value of cardiac troponin T and I in hemodialysis patients.
Kalaji FR; Albitar S
Saudi J Kidney Dis Transpl; 2012 Sep; 23(5):939-45. PubMed ID: 22982904
[TBL] [Abstract][Full Text] [Related]
18. The influence of gender, weight, height and BMI on pentosidine concentrations in plasma of hemodialyzed patients.
Slowick-Zylka D; Safranow K; Dziedziejko V; Dutkiewicz G; Ciechanowski K; Chlubek D
J Nephrol; 2006; 19(1):65-9. PubMed ID: 16523428
[TBL] [Abstract][Full Text] [Related]
19. Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites.
Klemm A; Franke C; Busch M; Müller A; Franke S; Lang D; Passlick-Deetjen J; Stein G
Clin Nephrol; 2004 Mar; 61(3):191-7. PubMed ID: 15077870
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms for the formation of glycoxidation products in end-stage renal disease.
Weiss MF; Erhard P; Kader-Attia FA; Wu YC; Deoreo PB; Araki A; Glomb MA; Monnier VM
Kidney Int; 2000 Jun; 57(6):2571-85. PubMed ID: 10844627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
